Programmed death-ligand 1 (PD-L1), HER2, and EGFR expression were successfully detected on circulating tumor cells (CTCs) in carcinoma patients using liquid biopsy–based molecular profiling.
Multi-marker analysis of circulating tumor cells enables simultaneous evaluation of clinically actionable therapeutic targets directly from blood samples.
Detection of PD-L1, HER2, and EGFR on CTCs provides valuable insights into tumor biology and potential treatment strategies across multiple cancer types.
CTC-based receptor profiling allows non-invasive monitoring of biomarker expression, reducing dependence on repeated tissue biopsies.
Dynamic assessment of therapeutic targets through liquid biopsy CTC profiling may help identify changes in tumor molecular characteristics during disease progression or treatment.
The approach enables real-time evaluation of treatment eligibility, particularly for therapies targeting EGFR, HER2, or immune checkpoint pathways.
Integrating CTC-based biomarker detection into clinical workflows may enhance personalized therapy selection and improve treatment outcomes.
Overall, multi-marker CTC profiling represents a promising tool for precision oncology diagnostics, targeted therapy selection, and longitudinal cancer monitoring.
Read Abstract